FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to an agonist of glucose-dependent insulinotropic polypeptide (GIP), and can be used in medicine. GIP agonist in accordance with the present invention can be acylated by conjugation thereof with a lipophilic substitute, which increases the in vivo half-life thereof by reducing sensitivity to proteolysis and reducing clearance, while maintaining binding affinity with the GIP receptor on a level sufficient for the therapeutic effect.
EFFECT: modified GIP agonist of the present invention can be used in treating diseases associated with metabolic disorders.
29 cl, 4 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
